Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases (Q36922689)

17 August 2017

1 reference

title

Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases (English)

1 reference

17 August 2017

0 references

Lynn W Kitchen

1

1 reference

PubMed ID

17728025

17 August 2017

David W Vaughn

series ordinal

2

1 reference

PubMed ID

17728025

17 August 2017

language of work or name

English

0 references

publication date

6 August 2007

1 reference

17 August 2017

1 reference

17 August 2017

25

1 reference

17 August 2017

7017-7030

1 reference

17 August 2017

41

1 reference

Protective Effect of Vaccination Against Induced Influenza A

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Swine Inftuenza A at Fort Dix, New Jersey (January-February 1976). I. Case Finding and Clinical Study of Cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Swine Influenza A at Fort Dix, New Jersey (January-February 1976). II. Transmission and Morbidity in Units with Cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Swine Influenza A at Fort Dix, New Jersey (January-February 1976). III. Extent of Spread and Duration of the Outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

History of U.S. military contributions to the study of respiratory infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Influenza at Lowry Air Force Base in Denver, 1982-1986

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Antigenic drift and efficacy of influenza virus vaccines, 1976--1977

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Antibody Response of Young Adults to Experimental Influenza A/ New Jersey/76 Virus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Efficacy of single-dose influenza in Air Force recruits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

History of U.S. military contributions to the study of vaccines against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Recovery of new agent from patients with acute respiratory illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Respiratory diseases among U.S. military personnel: countering emerging threats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Sulfadiazine-resistant group A Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Prevention of Meningococcal Disease by Group C Polysaccharide Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

History of U.S. military contributions to the study of viral hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Efficacy of azithromycin for typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Reduction of Mortality in Chloramphenicol-Treated Severe Typhoid Fever by High-Dose Dexamethasone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

History of U.S. military contributions to the study of diarrheal diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

The epidemiology of Japanese encephalitis: prospects for prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Protection against Japanese encephalitis by inactivated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Further experience with Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Prophylactic gamma globulin for prevention of endemic hepatitis. Effects of US gamma globulin upon the incidence of viral hepatitis and other infectious diseases in US Soldiers abroad

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Immunogenicity of an inactivated hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Hepatitis A in the US Army: epidemiology and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Scrub typhus vaccine candidate Kp r56 induces humoral and cellular immune responses in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Malaria vaccines in development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Experimental investigations regarding the etiology of dengue fever. 1907.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

HIV vaccines: new frontiers in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Role of US military research programs in the development of US Food and Drug Administration--approved antimalarial drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.030

10.1016/J.VACCINE.2007.07.030

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17728025